Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Running, not enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Head and Neck Squamous Cell Carcinoma

In brief

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.

Key facts

Study ID

NCT06082167

Run by

Exelixis

People needed

600

Starts

2024-06-07

Expected to finish

2029-03-01

Last updated by the study team

2025-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically-confirmed R/M HNSCC that is considered incurable by local therapy.
• Should not have had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy which was completed more than 6 months prior to randomization if given as part of multimodal treatment for locally advanced disease is allowed.
• The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, and larynx.
• PD-L1 expression level Combined Positive Score (CPS) ≥ 1.
• Participants with oropharyngeal cancer must have human papillomavirus (HPV) status from tumor tissue.
• Measurable disease according to RECIST 1.1 as determined by the Investigator.
• Tumor samples (archival or fresh tumor biopsy) are required. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization.
• Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
• Age 18 years (or the legal age of consent in your country, if higher than 18) or older on the day of consent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Adequate organ and marrow function.

You may not qualify if…

• Nasopharynx, salivary gland or occult primary site (regardless of p16 status).
• Has disease that is suitable for local therapy administered with curative intent.
• Has received prior therapy with zanzalintinib, any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (for example, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
• Life expectancy < 3 months.
• Had progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
• Radiation therapy for bone metastases within 2 weeks, any other radiation therapy within 4 weeks prior to randomization.
• Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to randomization.
• Positive hepatitis B surface antigen (HBsAg) test.
• Positive hepatitis C virus (HCV) antibody test.
• Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to randomization. Complete wound healing from major or minor surgery must have occurred at least prior to randomization.
• Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG) within 28 days before randomization.
• Pregnant or lactating females.
• Administration of a live, attenuated vaccine within 30 days before randomization.

Where it is running

• Exelixis Clinical Site #50 — Talca, Chile
• Exelixis Clinical Site #51 — Valdivia, Chile
• Exelixis Clinical Site #2 — Fullerton, California, United States
• Exelixis Clinical Site #1 — Orange City, Florida, United States
• Exelixis Clinical Site #163 — Tampa, Florida, United States
• Exelixis Clinical Site #123 — Athens, Georgia, United States
• Exelixis Clinical Site #82 — Atlanta, Georgia, United States
• Exelixis Clinical Site #19 — Chicago, Illinois, United States
• Exelixis Clinical Site #62 — Des Moines, Iowa, United States
• Exelixis Clinical Site #100 — Iowa City, Iowa, United States
• Exelixis Clinical Site #4 — St Louis, Missouri, United States
• Exelixis Clinical Site #148 — Lebanon, New Hampshire, United States
• Exelixis Clinical Site #158 — Camden, New Jersey, United States
• Exelixis Clinical Site #3 — Shirley, New York, United States
• Exelixis Clinical Site #95 — Durham, North Carolina, United States
• Exelixis Clinical Site #117 — Wilson, North Carolina, United States
• Exelixis Clinical Site #43 — Roanoke, Virginia, United States
• Exelixis Clinical Site #73 — Rosario, Santa Fe Province, Argentina
• Exelixis Clinical Site #91 — Buenos Aires, Argentina
• Exelixis Clinical Site # 47 — Ciudad Autonoma de Buenos Aire, Argentina
• Exelixis Clinical Site #53 — Ciudad Autonoma de Buenos Aire, Argentina
• Exelixis Clinical Site #93 — Córdoba, Argentina
• Exelixis Clinical Site #64 — Córdoba, Argentina
• Exelixis Clinical Site #157 — Pergamino, Argentina
• Exelixis Clinical Site #109 — Santiago, Chile

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.